Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

9.000 -0.090 (-0.99%)

Streaming Delayed Price Updated: 9:34 AM EDT, Jul 28, 2026 Add to My Watchlist

Price and Volume

Volume	1,110
Open	9.030
Bid (Size)	9.000 (100)
Ask (Size)	9.580 (100)
Prev. Close	9.090
Today's Range	9.000 - 9.050
52wk Range	6.465 - 12.74
Shares Outstanding	51,827,910
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 06, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-4.3%	-4.3%
1 Month	-2.9%	-2.9%
3 Month	+10.0%	+10.0%
6 Month	+1.7%	+1.7%
1 Year	-5.7%	-5.7%

More News

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 07, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued ↗

September 09, 2025

Via Stocktwits

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

March 23, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

March 17, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

March 12, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

March 02, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

Xilio Therapeutics Announces Pricing of Underwritten Offering

February 11, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

January 08, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

November 13, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

November 07, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

November 07, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 03, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

October 30, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

October 03, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

September 09, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Xilio Therapeutics, Inc. - Common Stock publicly traded?

Yes, Xilio Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Xilio Therapeutics, Inc. - Common Stock trade on?

Xilio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Xilio Therapeutics, Inc. - Common Stock?

The ticker symbol for Xilio Therapeutics, Inc. - Common Stock is XLO on the Nasdaq Stock Market

What is the current price of Xilio Therapeutics, Inc. - Common Stock?

The current price of Xilio Therapeutics, Inc. - Common Stock is 9.000

When was Xilio Therapeutics, Inc. - Common Stock last traded?

The last trade of Xilio Therapeutics, Inc. - Common Stock was at 07/28/26 09:34 AM ET

What is the market capitalization of Xilio Therapeutics, Inc. - Common Stock?

The market capitalization of Xilio Therapeutics, Inc. - Common Stock is 466.46M

How many shares of Xilio Therapeutics, Inc. - Common Stock are outstanding?

Xilio Therapeutics, Inc. - Common Stock has 466M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.